Latest Insider Transactions at Sagimet Biosciences Inc. (SGMT)
This section provides a real-time view of insider transactions for Sagimet Biosciences Inc. (SGMT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Sagimet Biosciences Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Sagimet Biosciences Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 23
2024
|
George Kemble Executive Chairman |
SELL
Open market or private sale
|
Direct |
23,625
-16.6%
|
$70,875
$3.17 P/Share
|
|
Jul 19
2024
|
George Kemble Executive Chairman |
SELL
Open market or private sale
|
Direct |
14,062
-8.99%
|
$42,186
$3.1 P/Share
|
|
Jul 19
2024
|
Elizabeth Rozek General Counsel and CCO |
SELL
Open market or private sale
|
Direct |
10,914
-6.37%
|
$32,742
$3.1 P/Share
|
|
Jul 19
2024
|
Eduardo Bruno Martins Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
8,357
-9.33%
|
$25,071
$3.1 P/Share
|
|
Mar 26
2024
|
David Happel President & CEO |
BUY
Open market or private purchase
|
Direct |
12,100
+1.86%
|
$60,500
$5.27 P/Share
|
|
Jan 29
2024
|
Scott D Sandell > 10% Shareholder |
BUY
Other acquisition or disposition
|
Indirect |
267,947
+50.0%
|
-
|
|
Jan 29
2024
|
Scott D Sandell > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
1,110,950
-61.04%
|
-
|
|
Jan 29
2024
|
New Enterprise Associates 13 LP > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
850,000
-22.08%
|
-
|
|
Jan 29
2024
|
Nea Partners 13, Limited Partnership > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
260,950
-100.0%
|
-
|
|
Jan 29
2024
|
Nea Partners 13, Limited Partnership > 10% Shareholder |
BUY
Other acquisition or disposition
|
Direct |
260,950
+50.0%
|
-
|
|
Jan 29
2024
|
Nea Partners 13, Limited Partnership > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
850,000
-22.08%
|
-
|
|
Jan 29
2024
|
Forest Baskett > 10% Shareholder |
BUY
Other acquisition or disposition
|
Indirect |
272,250
+50.0%
|
-
|
|
Jan 29
2024
|
Forest Baskett > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
1,110,950
-61.04%
|
-
|
|
Jan 29
2024
|
Patrick J Kerins > 10% Shareholder |
BUY
Other acquisition or disposition
|
Direct |
13,139
+50.0%
|
-
|
|
Jan 29
2024
|
Patrick J Kerins > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
1,110,950
-61.04%
|
-
|
|
Jan 29
2024
|
Patrick J Kerins > 10% Shareholder |
BUY
Other acquisition or disposition
|
Indirect |
260,950
+50.0%
|
-
|
|
Dec 07
2023
|
David Happel President & CEO |
BUY
Open market or private purchase
|
Direct |
1,600
+0.25%
|
$6,400
$4.1 P/Share
|
|
Nov 17
2023
|
Eduardo Bruno Martins Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
89,570
+50.0%
|
-
|
|
Nov 17
2023
|
David Happel President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
624,910
+49.98%
|
-
|
|
Nov 17
2023
|
George Kemble Executive Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
150,750
+49.08%
|
-
|
|
Nov 17
2023
|
Elizabeth Rozek General Counsel and CCO |
BUY
Grant, award, or other acquisition
|
Direct |
171,420
+50.0%
|
-
|
|
Nov 16
2023
|
David Happel President & CEO |
BUY
Open market or private purchase
|
Direct |
590
+50.0%
|
$1,180
$2.35 P/Share
|
|
Sep 07
2023
|
George Kemble Executive Chairman |
BUY
Exercise of conversion of derivative security
|
Direct |
5,630
+50.0%
|
$0
$0.79 P/Share
|
|
Jul 18
2023
|
New Enterprise Associates 13 LP > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
30,000
+0.77%
|
$480,000
$16.0 P/Share
|
|
Jul 18
2023
|
New Enterprise Associates 13 LP > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
662
-0.02%
|
$10,592
$16.0 P/Share
|
|
Jul 18
2023
|
New Enterprise Associates 13 LP > 10% Shareholder |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
13,404
+0.35%
|
$0
$0.79 P/Share
|
|
Jul 18
2023
|
New Enterprise Associates 13 LP > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
3,769,857
+49.75%
|
-
|
|
Jul 18
2023
|
New Enterprise Associates 13 LP > 10% Shareholder |
BUY
Other acquisition or disposition
|
Direct |
37,676
+50.0%
|
-
|
|
Jul 18
2023
|
New Enterprise Associates 13 LP > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
37,676
-100.0%
|
-
|
|
Jul 18
2023
|
Jinzi Jason Wu Director |
BUY
Conversion of derivative security
|
Indirect |
1,654,701
+50.0%
|
-
|
|
Jul 18
2023
|
Beth C Seidenberg Director |
BUY
Open market or private purchase
|
Indirect |
46,875
+50.0%
|
$750,000
$16.0 P/Share
|
|
Jul 18
2023
|
Beth C Seidenberg Director |
BUY
Conversion of derivative security
|
Direct |
84,768
+50.0%
|
-
|
|
Jul 18
2023
|
Beth C Seidenberg Director |
BUY
Conversion of derivative security
|
Indirect |
1,860,712
+49.48%
|
-
|
|
Jul 18
2023
|
Beth C Seidenberg Director |
BUY
Grant, award, or other acquisition
|
Indirect |
38,763
+50.0%
|
-
|
|
Jul 18
2023
|
Beth C Seidenberg Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
38,763
-100.0%
|
-
|
|
Jul 18
2023
|
Kpcb Pbd Associates, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
1,860,712
+49.48%
|
-
|
|
Jul 18
2023
|
Kpcb Pbd Associates, LLC > 10% Shareholder |
BUY
Other acquisition or disposition
|
Indirect |
38,763
+50.0%
|
-
|
|
Jul 18
2023
|
Kpcb Pbd Associates, LLC > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
38,763
-100.0%
|
-
|
|
Jul 18
2023
|
Merdad Parsey Director |
BUY
Conversion of derivative security
|
Direct |
4,117
+24.35%
|
-
|
|
Jul 18
2023
|
Merdad Parsey Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,677
+50.0%
|
-
|
|
Jul 18
2023
|
Merdad Parsey Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
8,677
-100.0%
|
-
|